Fasken acted as Canadian counsel to Zomedica Pharmaceuticals Corp. (Zomedica) in connection with the a public offering in the United States for common shares and warrants. Zomedica is an animal health company focused on meeting the needs of clinical veterinarians in ways that promote both patient and practice health.
Fasken advised Zomedica on Canadian securities law requirements in connection with their filling of a prospectus supplement to an accompanying prospectus filled in January 2019 with a team that included Bruce MacPhail and Matthew Bennett.
